PubMed

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.PMID: 16443869 [PubMed - indexed for MEDLINE]Related articlesFree article

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Johnson JA, Majumdar SR, Simpson SH, Toth EL.

Diabetes Care. 2002 Dec;25(12):2244-8.PMID: 12453968 [PubMed - indexed for MEDLINE]Related articlesFree article

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

Pharmacotherapy. 2005 Jun;25(6):810-6.PMID: 15927899 [PubMed - indexed for MEDLINE]Related articles

Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.

Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM.

Am J Med Sci. 2008 Sep;336(3):241-7.PMID: 18794619 [PubMed - indexed for MEDLINE]Related articles

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.

Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA.

CMAJ. 2006 Jan 17;174(2):169-74.PMID: 16415461 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

Diabetes Care. 2005 Oct;28(10):2345-51.PMID: 16186261 [PubMed - indexed for MEDLINE]Related articlesFree article

Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.

Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M.

Cardiology. 1999;91(3):195-202.PMID: 10516414 [PubMed - indexed for MEDLINE]Related articles

The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.

McAlister FA, Eurich DT, Majumdar SR, Johnson JA.

Eur J Heart Fail. 2008 Jul;10(7):703-8. Epub 2008 Jun 19.PMID: 18571471 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.

Koro CE, Bowlin SJ, Weiss SR.

Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):697-703.PMID: 15654719 [PubMed - indexed for MEDLINE]Related articles

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.

Johnson JA, Simpson SH, Toth EL, Majumdar SR.

Diabet Med. 2005 Apr;22(4):497-502.PMID: 15787679 [PubMed - indexed for MEDLINE]Related articles

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

Evans JM, Ogston SA, Emslie-Smith A, Morris AD.

Diabetologia. 2006 May;49(5):930-6. Epub 2006 Mar 9.PMID: 16525843 [PubMed - indexed for MEDLINE]Related articles

Medical therapy for diabetes is associated with increased use of lower endoscopy.

Lewis JD, Capra AM, Achacoso NS, Ferrara A, Levin TR, Quesenberry CP Jr, Habel LA.

Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1195-202.PMID: 17603822 [PubMed - indexed for MEDLINE]Related articles

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.PMID: 17551989 [PubMed - indexed for MEDLINE]Related articles

Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.

Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA.

Drugs Aging. 2008;25(7):611-22.PMID: 18582148 [PubMed - indexed for MEDLINE]Related articles

The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12.PMID: 17245800 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.

Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ Jr.

Diabetes Care. 2005 Jan;28(1):20-6.PMID: 15616228 [PubMed - indexed for MEDLINE]Related articlesFree article

Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.

Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW.

Drug Saf. 2009;32(8):675-90. doi: 10.2165/00002018-200932080-00006.PMID: 19591532 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.

Yurgin N, Secnik K, Lage MJ.

Clin Ther. 2007 Feb;29(2):316-25.PMID: 17472823 [PubMed - indexed for MEDLINE]Related articles

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.

Rao AD, Kuhadiya N, Reynolds K, Fonseca VA.

Diabetes Care. 2008 Aug;31(8):1672-8. Epub 2008 May 5.PMID: 18458139 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone and myocardial infarction in patients previously prescribed metformin.

Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM.

PLoS One. 2009 Jun 27;4(6):e6080.PMID: 19562036 [PubMed - indexed for MEDLINE]Related articlesFree article